DNA vaccines would be much easier to store than mRNA alternatives and should be as effective as conventional vaccines that contain live viruses
By Michael Le Page
A US company has filed for approval to test DNA vaccines in people
The first human trials of DNA vaccines designed to produce live viruses in people’s bodies could start next year. A US company called Medigen has told New Scientist it is seeking approval for such trials.
The aim is to combine the potential advantages of DNA vaccines, including rapid manufacturing and easy storage, with the greater efficacy of vaccines that consist of live weakened viruses.
“So instead of giving live virus, we would give a piece of DNA and …
View introductory offers
No commitment, cancel anytime*
Offer ends 28th October 2023.
*Cancel anytime within 14 days of payment to receive a refund on unserved issues.
Inclusive of applicable taxes (VAT)
Sign in to your account
More from New Scientist
Explore the latest news, articles and features